|
MechanismMPXV A35R inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
A multicenter, randomized, double-blind, placebo-controlled, phase II clinical study to evaluate the efficacy and safety of HL-21 tablets in adult patients with mild and moderate novel coronavirus infection (COVID-19).
Ultra-short treatment by advancing new regimens based on sitafloxacin and pyrazinamide for drug-susceptible pulmonary tuberculosis (UltraStar-SZ): A multi-arm, multi-stage, adaptive, multi-centre, randomised, controlled, open-label, non-inferiority trial
/ RecruitingNot ApplicableIIT Participate in the research on comprehensive early screening technology and clinical application of liver cancer and establish the application demonstration base of early screening and early diagnosis of liver disease in Shenzhen
100 Clinical Results associated with Shenzhen Third People's Hospital
0 Patents (Medical) associated with Shenzhen Third People's Hospital
100 Deals associated with Shenzhen Third People's Hospital
100 Translational Medicine associated with Shenzhen Third People's Hospital